Venrock Healthcare Capital Par Sells 39,986 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the firm’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $18.28, for a total value of $730,944.08. Following the completion of the transaction, the insider owned 5,089,354 shares of the company’s stock, valued at approximately $93,033,391.12. This represents a 0.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, March 25th, Venrock Healthcare Capital Par sold 174,645 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $16.95, for a total transaction of $2,960,232.75.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $19.33 on Monday. The stock has a market cap of $990.08 million, a price-to-earnings ratio of -4.89 and a beta of -0.35. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.23 and a 52 week high of $19.95. The company’s 50-day moving average price is $16.04 and its 200 day moving average price is $14.45. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

Analyst Upgrades and Downgrades

Several analysts have recently commented on KALV shares. Citizens Jmp lowered their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Thursday. HC Wainwright upped their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Stifel Nicolaus raised their price target on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Needham & Company LLC boosted their price target on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $32.60.

KalVista Pharmaceuticals News Roundup

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently modified their holdings of KALV. Seven Fleet Capital Management LP purchased a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth about $782,000. Invesco Ltd. lifted its stake in shares of KalVista Pharmaceuticals by 23.1% during the fourth quarter. Invesco Ltd. now owns 77,864 shares of the specialty pharmaceutical company’s stock valued at $1,258,000 after buying an additional 14,621 shares during the period. XTX Topco Ltd purchased a new position in shares of KalVista Pharmaceuticals during the fourth quarter valued at approximately $428,000. Vestal Point Capital LP boosted its position in KalVista Pharmaceuticals by 152.0% during the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock worth $30,524,000 after acquiring an additional 1,140,000 shares during the last quarter. Finally, Virtus Investment Advisers LLC boosted its position in KalVista Pharmaceuticals by 364.9% during the fourth quarter. Virtus Investment Advisers LLC now owns 40,414 shares of the specialty pharmaceutical company’s stock worth $653,000 after acquiring an additional 31,721 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.